Infectious disease diagnostics market seen reaching $21.25 billion by 2030

The global infectious disease in vitro diagnostics market is projected to grow from $16.13 billion in 2026 to $21.25 billion by 2030, driven by rising disease burden, molecular testing adoption and pandemic preparedness. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Infectious disease testing is central to faster diagnosis, treatment decisions and outbreak control. - The market outlook points to continued demand as governments, hospitals and labs expand screening and surveillance capacity. - The growth forecast signals more investment in molecular diagnostics, point-of-care testing and multiplex panels.

What happened: - The Business Research Company projected the infectious disease in vitro diagnostics market will rise from $16.13 billion in 2026 to $21.25 billion by 2030. - The forecast implies a 7.1% compound annual growth rate over the period. - The market was estimated at $15.1 billion in 2025. - The company also said the market grew at a 6.8% CAGR from 2025 to 2026.

The details: - Infectious disease in vitro diagnostics are laboratory tests run on blood, urine or swab samples to detect bacteria, viruses, fungi and parasites. - These tests help identify infections, monitor pathogens and support infection control and public health surveillance. - Growth during the historical period was driven by the global burden of infectious diseases, more hospital laboratories, demand for early and accurate diagnosis, improvements in immunoassay technology and government disease-control programs. - Future growth is expected to be supported by pandemic preparedness, wider use of molecular diagnostics, rising antimicrobial resistance, broader diagnostic lab networks and stronger healthcare screening protocols. - Expected market trends include rapid adoption of molecular diagnostics, point-of-care infectious testing, highly sensitive pathogen detection, multiplex diagnostic panels and expanded surveillance testing. - North America held the largest market share in 2025. - Asia-Pacific is projected to post the fastest growth through the forecast period. - The analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report release added market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - Download a free sample - View the full market report

Between the lines: - The forecast reflects a market where persistent infectious disease burden is colliding with higher expectations for speed, sensitivity and decentralized testing. - The emphasis on molecular and multiplex diagnostics suggests buyers want broader pathogen coverage and faster results from fewer tests. - The regional split suggests mature markets remain large, but demand growth is shifting toward faster-expanding health systems in Asia-Pacific. - The release cited World Health Organization data saying about 10.8 million people worldwide contracted tuberculosis in October 2024, with men at 55% of cases, women at 33% and children and adolescents at 12%. - The World Health Organization data also said 6.1% of TB cases were among people living with HIV. - Climate change has expanded the range of disease-carrying vectors such as mosquitoes, adding pressure on diagnostic demand.

What's next: - The market is expected to keep expanding as diagnostic labs widen coverage and healthcare systems intensify screening. - Pandemic preparedness and antimicrobial resistance could keep supporting investment in faster and more precise testing platforms. - The next competitive edge will likely come from tests that combine speed, sensitivity and multi-pathogen detection.